A Phase I Clinical Trial of mTOR Inhibition With Sirolimus for Enhancing NY-ESO-1 Protein With MIS416 Vaccine Induced Anti-Tumor Immunity in Ovarian, Fallopian Tube and Primary Peritoneal Cancer

Trial Profile

A Phase I Clinical Trial of mTOR Inhibition With Sirolimus for Enhancing NY-ESO-1 Protein With MIS416 Vaccine Induced Anti-Tumor Immunity in Ovarian, Fallopian Tube and Primary Peritoneal Cancer

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 30 Nov 2017

At a glance

  • Drugs Sirolimus (Primary) ; Cancer vaccine NY-ESO-1; MIS 416
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 24 Nov 2017 Planned initiation date changed from 15 Nov 2017 to 15 Dec 2017.
    • 20 Oct 2017 Planned initiation date changed from 15 Oct 2017 to 15 Nov 2017.
    • 25 Sep 2017 Planned initiation date changed from 15 Sep 2017 to 15 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top